Can Zanaflex Tablets Be Split in Half?
No, Zanaflex (tizanidine) tablets should not be routinely split, as the FDA label does not explicitly authorize tablet splitting and the complex food-effect pharmacokinetics of tizanidine make dose consistency critical for safety and efficacy. 1
Key Pharmacokinetic Concerns
The FDA label for Zanaflex explicitly warns that "food has complex effects on tizanidine pharmacokinetics" and that switching between different administration methods can result in "clinically significant differences" leading to "increased adverse events or delayed/more rapid onset of activity." 1 This pharmacokinetic sensitivity suggests that any alteration in tablet integrity—including splitting—could unpredictably affect drug absorption and clinical response.
Formulation-Specific Considerations
Zanaflex is available in two formulations:
- Tablets (4 mg): Composed of tizanidine hydrochloride with inactive ingredients including microcrystalline cellulose and anhydrous lactose 1
- Capsules (2,4, and 6 mg): Not designed for splitting
The 4 mg tablet formulation does not appear to be scored based on the FDA label description, which is a critical indicator that the manufacturer did not design or test this product for splitting. 1
Evidence Against Tablet Splitting
Research demonstrates that tablet splitting frequently results in dose non-uniformity. A study evaluating 11 commonly split tablets found that 8 of 11 products failed USP uniformity testing when split with a razor blade, and all hand-split tablets failed even more dramatically. 2 This dose variability is particularly concerning for tizanidine given its:
- Narrow therapeutic window: Single doses of 8 mg are effective, but the dose-related nature of adverse events requires careful titration starting at 4 mg 1
- Cardiovascular risks: Tizanidine can prolong the QT interval by blocking cardiac potassium channels (IKr), with potential for cardiac arrhythmias 3
- CNS effects: Somnolence is the most common adverse effect, and dose inconsistency could lead to unpredictable sedation or inadequate spasticity control
Dosing Flexibility Without Splitting
The FDA-approved dosing strategy does not require tablet splitting:
- Start with 4 mg single doses
- Increase gradually in 2-4 mg increments to optimize effect
- Repeat dosing at 6-8 hour intervals as needed (maximum 3 doses/24 hours)
- Maximum daily dose: 36 mg 1
If doses smaller than 4 mg are needed, the capsule formulation provides 2 mg strength as an alternative. 1
Clinical Bottom Line
Given the lack of scoring, the complex pharmacokinetics sensitive to formulation changes, documented problems with tablet splitting uniformity in general, and the cardiovascular/CNS safety profile of tizanidine, splitting Zanaflex tablets is not recommended. If lower doses are required, use the 2 mg capsule formulation or work within the approved 4 mg tablet dosing increments.